# Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors

> **NCT07639970** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Hua Pang** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- Head and Neck Cancer (H&N)
- Pancreatic Cancer
- Glioma

## Interventions

- **DRUG:** [⁶⁸Ga]Ga-HT547 and [¹⁷⁷Lu]Lu-HT547

## Key facts

- **NCT ID:** NCT07639970
- **Lead sponsor:** Hua Pang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-06
- **Final completion:** 2027-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639970, "Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07639970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*